What Does “Progression-Free Survival” Mean in Cancer?

By: David Grew MD MPH

“Progression-free survival is a way researchers measure how long a treatment can keep cancer from getting worse."

∗ ∗ ∗

If you have cancer, or love someone who does, you may have seen the term progression-free survival in an article, a clinical trial, a news headline, or a conversation with your doctor.

For many patients, it is one more piece of oncology language that sounds important, but feels hard to pin down. That is understandable.

It is also a term that can create real confusion. Patients sometimes assume progression-free survival means the same thing as cure. Others think it means overall survival. Still others hear that a treatment “improved progression-free survival” and have no idea whether that is a big deal or not.

So let’s break it down simply.

Progression-free survival, often shortened to PFS, is a way doctors and researchers measure how long a patient lives without the cancer growing, spreading, or getting worse. That’s it at the most basic level.

It does not necessarily mean the cancer is gone. It does not necessarily mean the patient lived longer overall. And it does not tell the full story by itself. But it can still be very useful. In this blog, I’ll explain what progression-free survival means, why it is used in cancer research, what it tells us, and where its limitations are.

What is progression-free survival?

Progression-free survival is the amount of time after starting treatment during which:

• the cancer does not get worse on scans or exams, and
• the patient is still alive

The phrase sounds technical, but the core idea is simple: How long did the treatment keep things from moving in the wrong direction?

If a treatment improves progression-free survival, it means patients receiving that treatment went longer, on average, before their cancer showed signs of worsening.

What does “progression” mean?

In cancer, progression usually means the disease has gotten worse. That may mean:

• the tumor got bigger
• a new tumor appeared
• cancer showed up in a new place
• existing disease spread further

Usually, doctors determine this based on imaging such as CT, MRI, or PET scans, along with symptoms and clinical judgment. So when we say a patient is progression-free, we mean that, based on the available evidence, the cancer has not clearly worsened.

Why do researchers use progression-free survival?

Because it helps answer an important question: Can this treatment keep cancer under control longer?

That matters, especially in cancers where cure is not always realistic and the goal is to control disease, preserve quality of life, and buy meaningful time.

Progression-free survival is used a lot in clinical trials because it can often be measured sooner than overall survival, which is the length of time patients live after treatment begins. In other words, researchers do not always have to wait many years to learn something useful. If one group’s cancer starts growing again much sooner than the other group’s, that may tell us the treatment made a difference.

Is progression-free survival the same as overall survival?

No. This is one of the most important distinctions for patients to understand.

Overall survival means how long patients live.

Progression-free survival means how long patients live without the cancer clearly getting worse.

Those are not the same thing. A treatment can improve progression-free survival without improving overall survival. That may sound strange at first, but it happens.

Why? Because patients may go on to get other treatments after progression. Or the treatment may delay worsening on scans without ultimately changing the length of life. Or the trial may simply not be large enough, or long enough, to detect a difference in overall survival.

This is why headlines about “improved progression-free survival” need a little nuance. It may be meaningful. Sometimes very meaningful. But it is not automatically the same as living longer.

Why can progression-free survival still matter if it does not always improve overall survival?

Because cancer care is not only about the final number of months or years. It is also about what that time feels like.

If a treatment can keep cancer stable longer, that may mean:

• fewer symptoms for a period of time
• more time before switching to a more intensive treatment
• more time before a hospitalization or major complication
• more time feeling like life is not being dictated by disease progression
  

That is not trivial. In some cases, longer progression-free survival can mean more time with a good quality of life. In other cases, the tradeoff may be less favorable if the treatment causes a lot of side effects.

So the real question is not just: Did PFS improve?

It is also: By how much? At what cost? And did patients feel better, worse, or about the same during that time?

How is progression-free survival measured?

In most clinical trials, patients get scans at planned intervals. Researchers then compare how long it takes before the cancer shows evidence of progression.

So if one treatment group goes longer before the cancer worsens, that group has better progression-free survival. Usually, this is reported as a median progression-free survival. That means the point in time when half the patients had experienced progression and half had not yet.

For example:

• Treatment A: median PFS 8 months
• Treatment B: median PFS 12 months
  

That means the treatment B group, on average, went about 4 months longer before the cancer worsened. That may be a meaningful difference. Or not. It depends on the setting, the side effects, the alternatives, and what kind of cancer we are talking about.

Is a longer progression-free survival always a big win?

Not necessarily. This is where medical judgment matters.

Sometimes an improvement in PFS is clearly important. For example, if the treatment delays progression substantially, is well tolerated, and gives patients more good-quality time, that is meaningful.

But sometimes the gain is small. If a treatment improves median progression-free survival by only a short amount and comes with major side effects, cost, or inconvenience, patients and doctors may reasonably disagree about how impressive that result really is.

This is one reason I encourage patients not to react to trial headlines in isolation. A result may be statistically significant without being life-changing.

What are the strengths of progression-free survival as a measure?

PFS has some real advantages.

• It can show treatment effects earlier. Researchers can often measure progression-free survival sooner than overall survival, which helps move cancer research forward more quickly.
• It can reflect disease control. For many cancers, especially advanced cancers, keeping the disease from worsening is a meaningful goal.
• It can help compare treatments. PFS can help doctors and researchers understand whether one treatment seems better than another at delaying progression.
• It may matter a great deal to patients. If progression means new symptoms, worsening pain, organ dysfunction, or the need for more toxic therapy, then delaying progression may matter quite a lot.
  

What are the limitations of progression-free survival?

This part is just as important.

• It is not the same as a cure. A treatment can improve PFS without curing the cancer.
• It is not the same as overall survival. Again, a PFS benefit does not automatically mean patients lived longer.
• Scan timing can influence the result. If scans are done at different intervals, that can affect when progression is detected.
• Some progression is easier to measure than others. A tumor getting bigger on CT is one thing. More subtle clinical worsening can be harder to standardize.
• It does not tell you how patients felt. A treatment may improve PFS but leave patients fatigued, nauseated, or otherwise burdened. That is why quality-of-life data matter so much.
  

What should patients ask when they hear that a treatment improved progression-free survival?

This is where the conversation becomes more useful. If you hear that a treatment improved PFS, some good questions are:

• By how much?
• Did it also improve overall survival?
• Did patients feel better, worse, or the same on treatment?
• What were the side effects?
• Was the benefit large enough to matter in real life?
• Is this relevant to my type of cancer and my stage of disease?
  

Those questions usually get you much closer to the truth than the phrase “improved progression-free survival” by itself.

–

Progression-free survival is a way of measuring how long a treatment keeps cancer from clearly getting worse. It is an important concept in oncology, but it is not a magic phrase and it does not stand alone. It is one way of describing benefit, not the only way.

The cleanest way to think about it is this: Progression-free survival tells us how long a treatment may hold the line.

Sometimes that is very meaningful. Sometimes less so. The real value depends on the bigger picture: symptoms, side effects, quality of life, overall survival, and what alternatives exist.

Patients deserve more than jargon. They deserve plain explanations of what these terms actually mean and why they matter.

Disclaimer: This is for educational purposes only. This is not medical advice. Talk to your doctor before making any medical decisions.

–

To learn more, browse our library of cancer related topics.

Hire PRIMR to create custom video content for your clinical trial or medical product today.

‍

FAQs:

Does progression-free survival mean the cancer is gone?

No. It means the cancer has not clearly worsened during that period of time. The cancer may still be present.

Is progression-free survival the same as remission?

Not exactly. Sometimes the two overlap, but they are not the same thing. A patient can be progression-free without having a complete remission.

Does improved progression-free survival mean patients lived longer?

Not always. Sometimes it does, and sometimes it does not. That is why overall survival is a separate and important outcome.

Why do clinical trials talk about progression-free survival so much?

Because it can often be measured sooner than overall survival and can still give useful information about whether a treatment is controlling the cancer.

Should patients care about progression-free survival?

Yes, but in context. It can be meaningful, especially if it comes with good quality of life and manageable side effects. The key is understanding how much benefit there was and what tradeoffs came with it.